Associated Papers
The role of the SLC25A15 transporter in the formation of liver metastasis in ESR1-mutated breast cancer.
Taya M et al.
Oncogene, 2026
Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years.
Diab E et al.
Breast (edinburgh, Scotland), 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial.
Blanc-Durand F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.
Herzog SK et al.
Cancer Research, 2026
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Lloyd MR et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
The natural L370F ERα variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells.
Cipolletti M et al.
Cell Communication and Signaling : Ccs, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer.
Lynce F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Comparative Performance of a Targeted Next-Generation Sequencing Assay Against Multiplexed Digital PCR Assays in Detecting ERBB2, ESR1, and PIK3CA Mutations in Plasma Circulating Cell-Free DNA from Liquid Biopsies.
Corné J et al.
The Journal of Molecular Diagnostics : Jmd, 2025
ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center.
Maloberti T et al.
The Journal of Liquid Biopsy, 2025
A ternary switch model governing ERα ligand binding domain conformation.
McDougal DP et al.
Nature Communications, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.
Òdena A et al.
Npj Precision Oncology, 2025
Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.
Jang M et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.
Cabel L et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries.
Devakrishnan AK et al.
Npj Breast Cancer, 2025
Evolutionary Overview and Future Perspectives: ESR1 Mutations, Liquid Biopsy, and Artificial Intelligence for a New Era of Personalized Medicine in ER+ Breast Cancer.
Martella S et al.
Molecular Diagnosis & Therapy, 2025
Uterine leiomyosarcoma progression: A study of serial recurrences.
Sia TY et al.
Gynecologic Oncology, 2025
Early phase development of PI3kinase inhibitors for anticancer therapies.
Caputo C et al.
Expert Opinion on Investigational Drugs, 2025
RPS24 microexon isoform as a novel biomarker for estrogen receptor-positive breast cancer progression and therapeutic resistance.
Park J et al.
Experimental & Molecular Medicine, 2025
Diagnostic utility of ESR1 mutation detection in liquid biopsy of metastatic breast cancer patients.
Sandbothe M et al.
Virchows Archiv : an International Journal of Pathology, 2025
AI-Driven Variant Annotation for Precision Oncology in Breast Cancer.
Shukla K et al.
Clinical and Translational Science, 2025
Molecular Landscape, Genomic Shift, and Prediction in the Neoadjuvant Setting of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Pons L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy in endocrine therapy-resistant breast cancer.
Wang M et al.
Neoplasia (new York, N.y.), 2025
Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.
Chaubal R et al.
Breast Cancer Research and Treatment, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.
Bidard FC et al.
The New England Journal of Medicine, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.
Klocker EV et al.
Npj Breast Cancer, 2025
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer.
Jeselsohn R et al.
Esmo Open, 2025
Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.
Chaki M et al.
Breast Cancer Research : Bcr, 2025